drugset / Trial / NCT00901498

Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

NCT00901498

Phase 1 Completed 36 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to assess the bioavailability of four experimental formulations relative to the current reference formulation used in the Phase 2 study.

Timeline

Start
2009-05
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Avagacestat Small molecule 150 mg Oral

Indications